Q1 2023 Non-GAAP Operating Income

AJOVY - Global Growth Quarterly Global Net Sales 2019 | 10 | 2020 2021 ■ Europe ■North America $95m Q1'23 UP 32% $72m Q1'22 2022 Q1'23 ■International Markets AJOVY (fremanezumab-vfrm) injection 225 mg/1.5 mL Net global sales of $95 million in Q1 2023: North America $49 million, +36% 24% U.S. market share Europe $36 million, +17% 30% market share International Markets $10 million, up 74% teva

View entire presentation